Dendreon (DNDN) Q2 misses on all counts
The company notes that the competitive environment remains largely unchanged from the first quarter.
Based upon current enrollment trends in July and August, it doesn't expect to see enough of a sales increase in H2 to meet its goal of growing Provenge Y/Y.
The company currently has $280.6M in cash, cash equivalents, and short-term and long-term investments, compared to $429.8M as of December 31, 2012.
Shares -12% AH.